SCHEMBL6067978

SCHEMBL6067978

NC(=O)CCCNC(=O)Nc1nc2ccc(Cl)cc2s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.58
FSCN1 Q16658 1/20 0.58
NPC1 O15118 6/20 0.57
RAB9A P51151 5/20 0.57
SMN1; SMN2 Q16637 5/20 0.57
PTPN1 P18031 1/20 0.56
CASP3 P42574 9/20 0.55
SENP7 Q9BQF6 9/20 0.55
SENP8 Q96LD8 8/20 0.55
SENP6 Q9GZR1 8/20 0.55
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
KDM4E B2RXH2 2/20 0.51
MAPT P10636 2/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
GAA P10253 1/20 0.51
ALOX12 P18054 1/20 0.51
HTT P42858 1/20 0.51
ABL1 P00519 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6067974 0.85 PTPN1 (0.67) DYRK1AFSCN1NPC1RAB9ASMN1; SMN2
SCHEMBL6067997 0.83 DYRK1A (0.71) DYRK1AFSCN1NPC1RAB9ASMN1; SMN2
SCHEMBL2790634 0.81 DYRK1A (0.64) DYRK1AFSCN1NPC1RAB9ASMN1; SMN2
Potassium Ion SCHEMBL2790230 0.79 DYRK1A (0.61) DYRK1AFSCN1NPC1RAB9ASMN1; SMN2
SCHEMBL27173084 0.77 DYRK1A (0.70) DYRK1AFSCN1NPC1RAB9ASMN1; SMN2
SCHEMBL29477209 0.77 DYRK1A (0.70) DYRK1AFSCN1NPC1RAB9ASMN1; SMN2
SCHEMBL6068064 0.77 RAB9A (0.58) DYRK1ANPC1RAB9ASMN1; SMN2MAPT
SCHEMBL6068055 0.75 RAB9A (0.60) DYRK1ANPC1RAB9ASMN1; SMN2MEN1
SCHEMBL6068110 0.75 ABL1 (0.80) DYRK1AFSCN1NPC1RAB9ASMN1; SMN2
SCHEMBL2791913 0.75 PTPN1 (0.69) DYRK1AFSCN1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7091227-B2 Benzothiazole derivatives ABBOTT GMBH & CO. KG (DE) 2006-08-15 US disclosed
US-20030153568-A1 Benzothiazole derivatives BASF AKTIENGESELLSCHAFT LUDWIGSHAFEN, GERMANY 2003-08-14 US disclosed
CN-1422262-A 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors ABBOTT GMBH & CO KG (DE) 2003-06-04 CN disclosed
EP-1254123-A1 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS Abbott GmbH & Co. KG (DE) 2002-11-06 EP disclosed
WO-2001057008-A1 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153568-A1 Benzothiazole derivatives TK1, FLT1, CDK1 DYRK1A 231/4885FSCN1 4525/4885NPC1 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.